FACIT
Venture capital · Toronto, Canada · North America
FACIT is a commercialization venture organization established by the Ontario Institute for Cancer Research that applies venture capital and market-driven investing to life science innovations in Ontario. It provides capital, executive management and industry connections to oncology companies, and manages a portfolio of Ontario oncology assets spanning therapeutics, imaging, diagnostics and technology platforms.
Invests inHealthcare & Biotech
In its own wordsoncologylife sciencesbiotechtherapeuticsdiagnosticscommercialization
Your fit with FACIT
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsFACIT lists 38 checked portfolio companies on its own site. Its largest themes are Healthcare & Biotech (88%), Education (8%) and Industrial & Manufacturing (3%). 79% of its companies are based in Canada. It invests most often alongside Creative Destruction Lab, Toronto Innovation Acceleration Partners and Spring.
No funding round on record names FACIT yet, so the figures come from its portfolio page.
Round figures show recent activity, not FACIT's whole history. Rounds on record name 0 companies; its own site lists 38. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 76th | 38 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 95th | 88% in its largest sector |
| Reach | 42th | 2 countries |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers3797%
- No longer answers00%
- Points to another company13%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 88% | 15% |
| Education | 8% | 7% |
| Industrial & Manufacturing | 3% | 7% |
| Cybersecurity | 3% | 4% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Creative Destruction Lab
Compare FACIT head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
38 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| 16-BIT develops AI-driven medical software for opportunistic screening and bone age assessment | Healthcare & Biotech | Portfolio page | ||
| 20/20 OptimEyes Technologies develops a drug delivery platform that delivers small-molecule drugs directly to mucosal surfaces | Healthcare & Biotech | Portfolio page | ||
| A.I. VALI INC. provides real-time AI solutions in medical imaging, including data collection and report generation for clinical and research applications. | Healthcare & Biotech | Portfolio page | ||
| AIGA Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation radioligand therapies (RLTs). | Healthcare & Biotech | Portfolio page | ||
| Arrayus is a medical technology company developing a non-invasive focused ultrasound therapy platform for oncological applications. | Healthcare & Biotech | Portfolio page | ||
| Block Biosciences is developing first-in-class therapeutics designed to intercept the spread of cancer to the brain. | Healthcare & Biotech | Portfolio page | ||
| Cura Therapeutics is developing the next generation of multimodal immunotherapies to treat metastatic cancers, pathogen infections, fibrotic diseases, and senescence | Healthcare & Biotech | Portfolio page | ||
| Dalriada Therapeutics accelerates drug discovery by decoding target druggability and providing data on small molecule interactions in live cells | Healthcare & Biotech | Portfolio page | ||
| DNAstack provides a federated insights platform for omics and health data | Healthcare & Biotech | Portfolio page | ||
| The company provides applications that improve knowledge, workflow, and collaboration for doctors | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Esphera SynBio modifies cells to produce modified exosomes for the treatment and prevention of disease. | Healthcare & Biotech | Portfolio page | ||
| Fusion Pharmaceuticals develops targeted alpha therapeutics for precision medicine to treat cancers | Healthcare & Biotech | Portfolio page | ||
| Genetics Adviser is a digital genetics platform built to increase access to genetic testing through patient-centered engagement and scalable, provider-supported workflows. | Healthcare & Biotech | Portfolio page | ||
| HDAX Therapeutics develops oral medicines that target HDAC6 for the treatment of various diseases, including renal, cardiometabolic and neurological diseases. | Healthcare & Biotech | Portfolio page | ||
| Hyivy Health connects an at-home therapeutic device, a patient app, and clinician-grade data to strengthen care delivery for pelvic health | Healthcare & Biotech | Portfolio page | ||
| ImmunoBiochem is developing novel degrader-antibody conjugate therapeutics for precision immunology | Healthcare & Biotech | Portfolio page | ||
| KA Imaging develops innovative X-ray imaging technologies and systems, providing solutions to the medical, veterinary, and non-destructive testing markets. | Healthcare & BiotechIndustrial & Manufacturing | Portfolio page | ||
| McMaster University is an educational institution that offers various academic programs and conducts research | Education | Portfolio page | ||
| The company conducts research | EducationHealthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- facit.ca
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Companies checked
- 38
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get FACIT's profile as data
Pull FACIT's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/facit.ca
# also
GET /v1/firms/facit.ca/portfolio
GET /v1/firms/facit.ca/coinvestors
GET /v1/firms/facit.ca/news